Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Ultra-rare disease: an European perspective

Sergio Harari, Marc Humbert
European Respiratory Review 2020 29: 200195; DOI: 10.1183/16000617.0195-2020
Sergio Harari
1U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria e Emodinamica Polmonare, Ospedale San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sergio Harari
  • For correspondence: sergio@sergioharari.it
Marc Humbert
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
4INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Too little attention is still paid to ultra-rare diseases. It is important to disseminate the best information on less common diseases in order to improve the clinical managment and improve care. https://bit.ly/2NougE5

In the past few years, interest in rare diseases has grown, as demonstrated by the agendas of politicians and health authorities, but too little attention is still paid to ultra-rare diseases. Although no legal definition of an “ultra-rare” disease has yet been established, this subcategory was informally introduced by the National Institute for Health and Care Excellence for drugs with indications for diseases that have a prevalence <1 per 50 000 persons [1–3].

In the respiratory field, there are several ultra-rare diseases, such as lymphangioleiomatosis, pleuro-parenchymal fibroelastosis, pulmonary alveolar microlithiasis, ataxia telangiectasia, pulmonary alveolar proteinosis, lysosomal storage diseases, pulmonary dendriform ossification, light chain deposition disorders, Birt–Hogg–Dubè syndrome, rare vascular disorders and vasculitis along with several others [4].

The research for new drugs to treat very rare diseases requires significant investments and the earmarking of highly sophisticated resources, a situation which raises ethical as well as social issues. It is indeed fair to wonder whether society and the public at large should bear the high cost of research activities benefiting a very small number of individuals, albeit affected by severe and chronic ailments, or whether this goes against the principle of equality (strangely enough patients with rare and often unknown conditions tend to absorb even higher resources than patients affected by more common diseases generally described as “normal”) [4].

An important issue is how research should be carried out for ultra-rare diseases, along with the issue of quality. Although less stringent criteria may be adopted for orphan drugs than for drugs treating more common diseases, this should not be an excuse not to guarantee the best possible treatments to patients with rare diseases [4, 5]. A well organised, patient-centred, multidisciplinary approach is more patient friendly and generates better outcomes than the current care model where patients with rare diseases see different specialists at different sites and at different times [6].

The European Respiratory Review has always paid much attention to ultra-rare disease, publishing selected reviews and series [4]. This year the journal is publishing a mini-series of reviews dealing with some ultra-rare respiratory conditions written by outstanding expert in the field: pulmonary capillary haemangiomatosis, cystic lung diseases and pulmonary alveolar microlithiasis. The first in the series, by Weatherald et al. [7], is published in the current issue of the European Respiratory Review.

It is not common that medical journals with a significant impact factor dedicate room to ultra-rare disease, because the number of citations for these topics can be low and the interest might be restricted to a particular audience of specialised readers. However, it is an important mission for a society journal to disseminate the best possible information on less common issues in order to improve awareness of more neglected area of research and support better care, education and translational research in the field of truly orphan diseases.

Footnotes

  • Provenance: Commissioned article, peer reviewed

  • Conflict of interest: S. Harari reports grants and personal fees from Roche, Actelion and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: M. Humbert reports personal fees from Acceleron, GSK, Merck, Novartis, AstraZeneca and Sanofi, and grants and personal fees from Actelion and Bayer, outside the submitted work.

  • Received June 16, 2020.
  • Accepted June 18, 2020.
  • Copyright ©ERS 2020.
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. National Institute for Health and Clinical Excellence
    . NICE Citizens Council Report Ultra Orphan Drugs. London, NICE, 2004.
    1. Huges DA,
    2. Tunnage B,
    3. Yeo ST
    . Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med 2005; 98: 829–836. doi:10.1093/qjmed/hci128
    OpenUrlCrossRefPubMed
  2. ↵
    1. National Institute for Health and Clinical Excellence
    . Appraising Orphan Drugs. London, NICE, 2008.
  3. ↵
    1. Harari S
    . Why we should care about ultra-rare disease. Eur Respir Rev 2016; 25: 101–103. doi:10.1183/16000617.0017-2016
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Joppi R,
    2. Bertele V,
    3. Garattini S
    . Orphan drug development is not taking off. Br J Clin Pharmacol 2009; 67: 494–502. doi:10.1111/j.1365-2125.2009.03369.x
    OpenUrlCrossRefPubMed
  5. ↵
    1. Van Groenendael S,
    2. Giacovazzi L,
    3. Davison F, et al.
    High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease. Orphanet J Rare Dis 2015; 10: 149. doi:10.1186/s13023-015-0366-y
    OpenUrlCrossRefPubMed
  6. ↵
    1. Weatherald J,
    2. Dorfmüller P,
    3. Perros F, et al.
    Pulmonary capillary haemangiomatosis: a distinct entity? Eur Respir Rev 2020; 29: 190168.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 29 Issue 156 Table of Contents
European Respiratory Review: 29 (156)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Ultra-rare disease: an European perspective
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Ultra-rare disease: an European perspective
Sergio Harari, Marc Humbert
European Respiratory Review Jun 2020, 29 (156) 200195; DOI: 10.1183/16000617.0195-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Ultra-rare disease: an European perspective
Sergio Harari, Marc Humbert
European Respiratory Review Jun 2020, 29 (156) 200195; DOI: 10.1183/16000617.0195-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Chronic hypersensitivity pneumonitis: a frequently fatal disease
  • Magnetic resonance imaging in PH
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2021 by the European Respiratory Society